Activating Oncolytic Immunotherapies

About Us

OncoMyx Therapeutics is developing oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have emerged as a safe and effective IO complement.

Our MYXV platform, spun-out from Arizona State University (ASU), is poised to be a best-in-class OV approach. We have assembled the top OV team around MYXV to advance a pipeline of oncology therapeutics for the benefit of cancer patients.

OVs are emerging as a new pillar of cancer care to complement the effectiveness of immunotherapies such as immune checkpoint blockade. The best-in-class MYXV platform is the only OV in development that is collectively a non-human pathogen, inherently immuno-stimulatory, easily multi-armed, and systemically delivered.


To develop oncolytic immunotherapies with an unambiguous, promotable advantage that eradicate hard-to-cure cancers.


OncoMyx’s proprietary therapeutic platform is backed by over 30 peer-reviewed publications by ASU Professor Grant McFadden and his collaborators evaluating a poxvirus called myxoma virus (MYXV) as an oncolytic agent in a wide variety of tumor models.

Best-in-Class Features:

  1. Non-Human Pathogen: MYXV is a potent and safe non-human pathogen
  2. Immuno-Stimulatory: inherently immuno-stimulatory against human tumors
  3. Ability to Multi-Arm: multiple therapeutic transgenes orchestrate an immune response
  4. Systemic Delivery: via either direct IV or our novel delivery using leukocyte carrier cells

Our therapeutic pipeline includes both monotherapies and therapies to be used in combination with immune checkpoint blockade and other immuno-modulatory approaches, offering significant therapeutic promise to a wide range of cancer targets.


Founders Steve Potts, Grant McFadden and Michael Wood have a track record of building teams to advance scientific breakthroughs and create significant shareholder value. OncoMyx has assembled the industry’s most experienced OV-specific oncology team.

Steve Potts

Steve Potts, PhD, MBA

Founder, CEO & Director
Michael Wood

Michael Wood, MBA

Founder & COO
Leslie Sharp

Leslie Sharp, PhD

Chief Scientific Officer
Grant McFadden

Grant McFadden, PhD

Founder, Research Advisor & Director
James Burke

James Burke, MD

Medical Advisor
George Roth

Georg Roth, PhD

CMC Advisor

Ursula Fritsch, PharmD

Regulatory Advisor
John Wallen

John Wallen, JD, PhD

Intellectual Property Advisor
Matt Fust

Matt Fust, MBA

Finance Advisor

Board of Directors

Steve Potts, PhD, MBA

Grant McFadden, PhD

Kanad Das, PhD

Tim Xiao, CFA, FRM

Jason Rushton


Scientific Advisory Board

Tobias Bald, Ph.D.

Neil Gibson, Ph.D.

Grant McFadden, Ph.D.

Ronan O’Hagan, Ph.D.

Dominic Spinella, Ph.D.



boehringer ingelheim

delos capital

xeraya capital

Korea Investment Partners

city hills ventures

madison partners llc

News & Publications

OncoMyx: 2019 Fast Lane Honoree


April 29, 2019

Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival

J Clin Invest. 2019.

Read More >

March 28, 2019

Poxvirus oncolytic virotherapy

Expert Opinion on Biological Therapy, DOI: 10.1080/14712598.2019.1600669

Read More >

December 4, 2016

Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor

Molecular Therapy Oncolytics.

Read More >

September 6, 2013

Oncolytic myxoma virus: The path to clinic

Published by Elsevier Ltd.

Read More >

April 1, 2012

Myxoma Virus Sensitizes Cancer Cells to Gemcitabine and Is an Effective Oncolytic Virotherapeutic in Models of Disseminated Pancreatic Cancer

Molecular Therapy vol. 20 no. 4, 759–768 apr. 2012 759

Read More >


We are actively hiring across multiple roles and disciplines and are working to build a world-class team that shares our commitment to help make a difference in patients’ lives through breakthrough science and medicines. If you are looking for your next career move and are interested in being part of a young, dynamic company where you could have a significant and long-term impact, please see our open positions. Please direct resumes to